At a glance
- Originator Nonindustrial source
- Class Anxiolytics; Nootropics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Learning disorders
Most Recent Events
- 25 Aug 1998 No-Development-Reported for Anxiety disorders in Russia (Unknown route)
- 25 Aug 1998 No-Development-Reported for Learning disorders in Russia (Unknown route)
- 20 Feb 1996 PV 113 is being investigated for use in Alzheimer's Disease and Cognition Disorders